A Korn1, B Wagner, E Moritz, J Dingemanse. 1. Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria.
Abstract
OBJECTIVE: The objectives of this double-blind study were to assess the tolerability and i.v. tyramine pressor response during combined treatment with moclobemide and selegiline. SUBJECTS: Two parallel groups of 12 healthy male and female subjects were treated with 200 mg moclobemide or 5 mg selegiline b.d. for 14 days. On Day 7, selegiline or moclobemide was added to the other treatment. IV tyramine pressor tests were conducted at baseline and at steady state during mono- and combined treatment. RESULTS: Treatment with moclobemide and selegiline alone was well tolerated, whereas combined treatment led to a slight increase in adverse events. Tyramine pressor sensitivity during moclobemide, selegiline and moclobemide + selegiline treatment was enhanced, on average, by 2.4-, 1.3- and 8.4-times, respectively. CONCLUSION: Although combined treatment with moclobemide and selegiline was well tolerated, the supra-additive potentiation of the tyramine pressor effects means that dietary restriction of tyramine intake will be necessary during such combination therapy.
RCT Entities:
OBJECTIVE: The objectives of this double-blind study were to assess the tolerability and i.v. tyramine pressor response during combined treatment with moclobemide and selegiline. SUBJECTS: Two parallel groups of 12 healthy male and female subjects were treated with 200 mg moclobemide or 5 mg selegiline b.d. for 14 days. On Day 7, selegiline or moclobemide was added to the other treatment. IV tyramine pressor tests were conducted at baseline and at steady state during mono- and combined treatment. RESULTS: Treatment with moclobemide and selegiline alone was well tolerated, whereas combined treatment led to a slight increase in adverse events. Tyramine pressor sensitivity during moclobemide, selegiline and moclobemide + selegiline treatment was enhanced, on average, by 2.4-, 1.3- and 8.4-times, respectively. CONCLUSION: Although combined treatment with moclobemide and selegiline was well tolerated, the supra-additive potentiation of the tyramine pressor effects means that dietary restriction of tyramine intake will be necessary during such combination therapy.
Authors: S Wijnands; P C Chang; G J Blauw; J van den Krogt; R Gieschke; M P Schoerlin; P van Brummelen Journal: J Psychopharmacol Date: 1989-01 Impact factor: 4.153
Authors: A D Van Haarst; J M Van Gerven; A F Cohen; M De Smet; A Sterrett; K L Birk; A L Fisher; M E De Puy; M R Goldberg; D G Musson Journal: Br J Clin Pharmacol Date: 1999-08 Impact factor: 4.335